← Back
FeaturedImmunology

Sparsentan (Filspari)

Travere Therapeutics

Dual endothelin/angiotensin receptor antagonist. FDA approved in IgAN. PROTECT Phase 3 confirmatory eGFR data ongoing.

IgA Nephropathy

Linked Studies

NCT04287985PrimaryCOMPLETEDPHASE2

Safety and Efficacy Study of VIS649 for IgA Nephropathy

Immunoglobulin A NephropathyGlomerular DiseaseUpdated Apr 2026
Loading comments…

Also Known As

Other names

sparsentan
Search all trials →Request coverage update